According to Huaxi Biotech, recently, the company's strategic investment in Korea's botulinum toxin INIBO was approved by the State Drug Administration, and the company is its sole partner in the mainland China market. This business development is another step for Huaxi Biotech to further expand its business areas and improve the pharmaceutical and medical device business layout on the basis of the existing medical and aesthetic industry.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.